



LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

Corporate Identity Number: L24100MH1983PLC029442

Tel: (91-22) 6640 2323

E-mail: info@lupin.com

Website: www.lupin.com

LUPIN

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Particulars	(₹ in million)				
	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended
	31/03/2026 (Audited) (Refer note 10)	31/12/2025 (Unaudited)	31/03/2025 (Audited) (Refer note 10)	31/03/2026 (Audited)	31/03/2025 (Audited)
1) Revenue from operations					
a) Sales / income from operations	51,522.6	44,339.6	43,826.9	190,444.2	164,585.8
b) Other operating income	823.4	672.3	1,029.8	4,682.4	5,089.2
Total Revenue from operations	52,346.0	45,011.9	44,856.7	195,126.6	169,675.0
2) Other income	888.3	998.0	487.9	3,127.7	1,740.5
3) Total income (1+2)	53,234.3	46,009.9	45,344.6	198,254.3	171,415.5
4) Expenses					
a) Cost of materials consumed	9,955.3	9,095.5	9,236.0	36,783.6	37,167.2
b) Purchases of stock-in-trade	2,745.8	2,961.3	2,777.4	11,923.2	12,468.5
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade [(increase)/decrease]	(335.1)	(175.2)	(256.5)	46.6	(383.5)
d) Employee benefits expense	6,606.5	6,315.1	5,524.2	25,448.8	23,120.7
e) Finance cost	387.7	360.2	338.5	1,214.7	845.0
f) Depreciation, amortisation and impairment expense (Refer note 7)	1,770.5	1,786.8	2,079.8	7,071.8	6,476.9
g) Other expenses (Refer note 5 and 6)	13,667.5	11,321.8	10,131.2	49,159.8	43,370.7
h) Net (gain) / loss on foreign currency transactions	(3,110.1)	(673.4)	(16.9)	(6,271.0)	(793.4)
Total expenses	31,688.1	30,992.1	29,813.7	125,377.5	122,272.1
5) Profit before exceptional item and tax (3-4)	21,546.2	15,017.8	15,530.9	72,876.8	49,143.4
6) Exceptional items (Refer note 4)	4,477.3	(6,338.4)	-	4,065.7	(772.2)
7) Profit before tax (5+6)	26,023.5	8,679.4	15,530.9	76,942.5	48,371.2
8) Tax expense					
Current tax (net)	4,711.2	1,414.0	2,702.5	13,512.9	8,571.2
Deferred tax (net)	(324.6)	90.9	(85.1)	(236.0)	70.4
Total tax expense	4,386.6	1,504.9	2,617.4	13,276.9	8,641.6
9) Net Profit after tax (7-8)	21,636.9	7,174.5	12,913.5	63,665.6	39,729.6
10) Other comprehensive income / (loss)					
(a) (i) Items that will not be reclassified subsequently to profit or loss	46.4	(77.4)	(178.7)	61.8	(222.4)
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	(16.2)	27.0	62.4	(21.6)	77.7
(b) (i) Items that will be reclassified subsequently to profit or loss	53.7	(12.9)	-	(324.3)	-
(ii) Income tax relating to items that will be reclassified to profit or loss	(18.8)	4.5	-	113.3	-
Other comprehensive income / (loss), net of tax	65.1	(58.8)	(116.3)	(170.8)	(144.7)
11) Total comprehensive income / (loss), net of tax (9+10)	21,702.0	7,115.7	12,797.2	63,494.8	39,584.9
12) Paid up equity share capital (Face value ₹ 2/- each)	914.4	913.7	913.2	914.4	913.2
13) Other equity				300,423.3	241,869.2
14) Earnings per share (Face value of ₹ 2/- each) (Not annualised for the quarters)					
(A) Before exceptional items					
a) Basic (in ₹)	37.01	27.16	28.30	129.18	88.80
b) Diluted (in ₹)	36.92	27.09	28.21	128.84	88.48
(B) After exceptional items					
a) Basic (in ₹)	47.35	15.71	28.30	139.38	87.10
b) Diluted (in ₹)	47.24	15.67	28.21	139.01	86.79

See accompanying notes to the standalone financial results.

continued on Page 2..

NOTES:

1. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on May 07, 2026.
2. The Board of Directors have, at its meeting held on May 07, 2026 recommended a dividend of ₹ 18/- per equity share of the face value of ₹ 2/- each aggregating ₹ 8,229.2 million. The recommended dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting.
3. During the quarter ended March 31, 2026, 380,305 (year to date 614,066) equity shares of ₹ 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up equity share capital by ₹ 0.7 million (year to date ₹ 1.2 million) and securities premium account by ₹ 463.2 million (year to date ₹ 719.7 million).
4. Exceptional items
 - a. The Company and its subsidiary are exposed to multiple civil lawsuits alleging anticompetitive behavior related to certain products and a possible violation of federal and state antitrust laws. These lawsuits were combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the quarter ended 31 December 2025, the Company on best estimate recorded a provision of ₹ 4,493.9 million (USD 50.0 million) towards this litigation without admission of liability or wrongdoing. During the quarter ended 31 March 2026, this provision has been recorded by the subsidiary and consequently reversed in the standalone results. In April 2026, the wholly owned subsidiary settled one of the ongoing dispute for an amount of ₹ 2,654.1 million (USD 30.0 million) without admission of liability or wrongdoing.
 - b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets and agreed to pay USD 90.0 million. During the quarter ended December 31, 2025 and year ended March 31, 2026, the Company has compensated LPI for the settlement payment of ₹ 1,364.7 million (USD 15.0 million) made by it and accordingly expensed. The balance amount of USD 75.0 million towards prepaid option has been paid and capitalised by the subsidiary.
 - c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of ₹ 496.4 million during the quarter ended December 31, 2025 and year ended March 31, 2026. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.
 - d. During the year ended March 31, 2026, the Company has transferred its Over the Counter ('OTC') and API R&D business in India to its wholly owned subsidiaries Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively, as a going concern on slump sale basis for a consideration of ₹ 8,200.0 million and ₹ 180.0 million resulting in gain on divestment of ₹ 6,589.6 million and ₹ 37.2 million respectively.
As at March 31, 2025, assets and liabilities related to transfer of such business were shown as "Assets held for sale".
 - e. During the year ended March 31, 2026, the Company has determined that the carrying value of investment in a subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of ₹ 700.0 million. During the year ended March 31, 2025, the Company had provided for diminution in the value of investments in subsidiaries of ₹ 772.2 million.
5. During the year ended March 31, 2025, the Company has transferred its generic business in India to its wholly owned subsidiary Lupin Life Sciences Limited (formerly known as Lupin Atharv Ability Limited), as a going concern on slump sale basis resulting in loss on divestment of ₹ 6.4 million.
6. During the year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of ₹ 750.5 million (USD 9.0 million) in connection with the drug Glumetza® without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation.
7. During the quarter and year ended March 31, 2025, the Company has recognised an impairment charge of ₹ 410.9 million related to property, plant and equipment, commercialised intangibles and capital work in progress.

continued on Page 3..

8. Standalone Balance Sheet:

Particulars	(₹ in million)	
	As at 31/03/2026 (Audited)	As at 31/03/2025 (Audited)
A. ASSETS		
1) Non-Current Assets		
a. Property, Plant and Equipment	31,685.1	34,456.7
b. Capital Work-in-Progress	4,294.3	2,319.0
c. Right-of-use-Assets	6,273.3	3,447.5
d. Goodwill	-	-
e. Intangible Assets	10,767.3	11,554.4
f. Intangible Assets Under Development	931.7	464.7
g. Financial Assets		
(i) Non-Current Investments		
- In Subsidiaries (Refer note 4e)	121,370.9	108,919.9
- In Others	634.6	594.8
(ii) Non-Current Loans	1,271.1	1,282.7
(iii) Other Non-Current Financial Assets	26,052.6	743.9
h. Non-Current Tax Assets (Net)	396.2	426.9
i. Other Non-Current Assets	1,401.2	1,163.8
Total Non-Current Assets	205,078.3	165,374.4
2) Current Assets		
a. Inventories	33,507.8	32,272.2
b. Financial Assets		
(i) Current Investments	34,247.7	10,035.6
(ii) Trade Receivables	69,220.3	56,643.5
(iii) Cash and Cash Equivalents	1,116.3	3,418.0
(iv) Other Bank Balances	164.4	1,167.8
(v) Current Loans	1,023.7	345.7
(vi) Other Current Financial Assets	6,405.9	3,919.8
c. Current Tax Assets (Net)	4.3	-
d. Other Current Assets	10,260.2	9,012.7
e. Assets included in disposal group held for sale (Refer note 4d)	-	2,130.2
Total Current Assets	155,950.6	118,945.5
TOTAL ASSETS	361,028.9	284,319.9
B. EQUITY AND LIABILITIES		
1) Equity		
a. Equity Share Capital	914.4	913.2
b. Other Equity	300,423.3	241,869.2
Total Equity	301,337.7	242,782.4
Liabilities		
I) Non-Current Liabilities		
a. Financial Liabilities		
(i) Lease Liabilities	3,906.5	1,899.8
(ii) Other Non-Current Financial Liabilities	316.0	358.6
b. Non-Current Provisions	4,527.8	3,985.0
c. Deferred Tax Liabilities (Net)	1,225.1	1,552.9
d. Other Non-Current Liabilities	1,392.5	743.8
Total Non-Current Liabilities	11,367.9	8,540.1
II) Current Liabilities		
a. Financial Liabilities		
(i) Current Borrowings	5,768.8	-
(ii) Lease Liabilities	1,476.0	601.5
(iii) Trade Payables		
- Total outstanding dues of micro enterprises and small enterprises	1,335.0	764.6
- Total outstanding dues of creditors other than micro enterprises and small enterprises	23,952.4	18,923.1
(iv) Other Current Financial Liabilities	4,635.4	2,880.8
b. Other Current Liabilities	3,855.7	3,915.7
c. Current Provisions	1,733.9	1,793.6
d. Current Tax Liabilities (Net)	5,566.1	3,445.9
e. Liabilities included in disposal group held for sale (Refer note 4d)	-	672.2
Total Current Liabilities	48,323.3	32,997.4
Total Liabilities	59,691.2	41,537.5
TOTAL EQUITY AND LIABILITIES	361,028.9	284,319.9

continued on Page 4..

9. Standalone Statement of Cash Flows:

Particulars	(₹ in million)	
	Year ended 31/03/2026 (Audited)	Year ended 31/03/2025 (Audited)
A. Cash Flow from Operating Activities		
Profit before Tax	76,942.5	48,371.2
Adjustments for:		
Depreciation, Amortisation and Impairment Expense	7,071.8	6,476.9
Loss / (Profit) on Sale / Write-off of Property, Plant and Equipment / Intangible Assets	(33.0)	(31.2)
Loss/(Profit) on Divestment of Business Undertaking	(6,626.8)	6.4
Gain on Sale of Investments	(941.6)	(416.2)
Finance Costs	1,214.7	845.0
Interest on Deposits with Banks and Others	(797.8)	(742.1)
Interest on Income Tax Refund	-	(24.1)
Unrealised Loss / (Gain) on Investments	(541.2)	(9.5)
Unrealised Loss / (Gain) on Non-Current Investment	(20.3)	(6.6)
Doubtful Trade Receivables / Advances provided	291.9	(63.9)
Bad Trade Receivables / Advances Written off	(1.9)	359.6
Share Based Payments Expense	131.2	173.1
Impairment in value of Non-Current investments	700.0	772.2
Unrealised Exchange Loss / (Gain) on Revaluation	(3,814.9)	(218.4)
Operating Profit before Working Capital Changes	73,574.6	55,492.4
Changes in working capital:		
(Increase) / Decrease in Inventories	(1,367.3)	(3,027.2)
(Increase) / Decrease in Trade Receivables	(8,774.5)	(17,945.5)
(Increase) / Decrease in Other Asset	(3,294.6)	553.2
Increase / (Decrease) in Trade Payables	5,271.5	(333.9)
Increase / (Decrease) in Other Liabilities	1,547.5	(2,210.6)
Cash Generated from Operations	66,957.2	32,528.4
Net Income tax paid	(11,558.7)	(8,081.9)
Net Cash Flow generated from / (used in) Operating Activities	55,398.5	24,446.5
B. Cash Flow from Investing Activities		
Payment for Purchase of Business	(95.6)	(91.3)
Payment for acquisition of Property, Plant and Equipment (including capital work-in-progress, other intangible assets, intangible assets under development, capital advances and capital creditors)	(7,170.4)	(12,943.8)
Proceeds from Sale of Property, Plant and Equipments / Intangible Assets	2,606.1	98.6
Proceeds from Disposal of Business Undertaking Net of Cash and Cash Equivalent	8,380.0	1,100.0
Investments in subsidiaries	(38,531.1)	(4,038.2)
Purchase of Investment	(162,009.9)	(149,701.0)
Proceeds from Sale of Investments	139,261.2	149,752.8
Change in other bank balance and cash not available for immediate use	1,003.4	(1,018.4)
Loan given to Subsidiaries	(1,750.0)	(1,802.5)
Loan Repaid by Subsidiaries	1,050.0	252.5
Interest Received	767.4	728.1
Net Cash Flow generated from / (used in) Investing Activities	(56,488.9)	(17,663.2)
C. Cash Flow from Financing Activities		
Proceeds from / (Repayment of) Current Borrowings	5,768.8	(181.3)
Proceeds from Issue of Equity Shares (including Share Application Money)	164.6	398.6
Payment of Principal Portion of Lease Liabilities	(953.8)	(678.0)
Interest Paid on Lease Liabilities	(265.4)	(160.8)
Finance Costs Paid	(442.1)	(327.7)
Dividend Paid	(5,483.4)	(3,653.1)
Net Cash Flow generated from / (used in) Financing Activities	(1,211.3)	(4,602.3)
Net Increase / (Decrease) in Cash and Cash Equivalents	(2,301.7)	2,181.0
Cash and Cash Equivalents as at the Beginning of the Year	3,418.0	1,237.0
Unrealised loss / (gain) on Foreign Currency Cash and Cash Equivalents	-	-
Cash and Cash Equivalents as at End of the Year	1,116.3	3,418.0

continued on Page 5..

10. The figures for the quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2025 and December 31, 2024 respectively.

By Order of the Board
For **Lupin Limited**

Nilesh
Deshband
hu Gupta

Digitally signed by
Nilesh Deshbandhu
Gupta
Date: 2026.05.07
19:29:39 +05'30'

Nilesh D. Gupta
Managing Director
DIN: 01734642

Place : Mumbai
Date : May 07, 2026

Independent Auditor's Report

To the Board of Directors of Lupin Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Lupin Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and

Registered Office:

Independent Auditor's Report (*Continued*)

Lupin Limited

presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Independent Auditor's Report (Continued)

Lupin Limited

Other Matter

- a. The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Sudhir
Murlidhar
Soni

Digitally signed by
Sudhir Murlidhar
Soni
Date: 2026.05.07
20:07:25 +05'30'

Sudhir Soni

Partner

Mumbai

07 May 2026

Membership No.: 041870

UDIN:26041870BEHJAJ5256